These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 31493989)

  • 1. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
    Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
    Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
    Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
    Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
    Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
    Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
    Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
    Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
    Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.
    Xu X; Ge R; Li L; Wang J; Lu X; Xue S; Chen X; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():1325-1344. PubMed ID: 29117897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.
    Wang A; Wang Y; Meng X; Yang Y
    Bioorg Med Chem; 2021 Feb; 31():115953. PubMed ID: 33388655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
    Saito Y; Mizokami A; Tsurimoto H; Izumi K; Goto M; Nakagawa-Goto K
    Eur J Med Chem; 2018 Sep; 157():1143-1152. PubMed ID: 30189396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.
    Xu X; Du Q; Meng Y; Li Z; Wu H; Li Y; Zhao Z; Ge R; Lu X; Xue S; Chen X; Yang Y; Wang J; Bian J
    Eur J Med Chem; 2020 Apr; 192():112196. PubMed ID: 32169785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.
    Yu J; Zhou P; Hu M; Yang L; Yan G; Xu R; Deng Y; Li X; Chen Y
    Eur J Med Chem; 2019 Nov; 182():111608. PubMed ID: 31437779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor antagonists and anti-prostate cancer activities of some synthesized steroidal candidates.
    Bahashwan SA; Al-Omar MA; Ezzeldin E; Abdalla MM; Fayed AA; Amr AG
    Chem Pharm Bull (Tokyo); 2011; 59(11):1363-8. PubMed ID: 22041072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel selective agents for the degradation of AR/AR-V7 to treat advanced prostate cancer.
    Yang Y; Lv G; Xiu R; Yang H; Wang W; Yu P; Zhang J; Ye L; Wang H; Tian J
    Eur J Med Chem; 2024 May; 271():116400. PubMed ID: 38626524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel androgen receptor antagonists: a hybrid approach of pharmacophore-based and docking-based virtual screening.
    Liu J; Liu B; Guo G; Jing Y; Zhao G
    Anticancer Drugs; 2015 Aug; 26(7):747-53. PubMed ID: 25933245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel 5-methyl-1H-pyrazole derivatives as potential antiprostate cancer agents: Design, synthesis, molecular modeling, and biological evaluation.
    Zhang D; Asnake S; Zhang J; Olsson PE; Zhao G
    Chem Biol Drug Des; 2018 Jun; 91(6):1113-1124. PubMed ID: 29388326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
    Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
    Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
    Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
    J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.